September 18th, 2014 · Leave a Comment
John Noseworthy, M.D., CEO and president of Mayo Clinic, and Tom Brokaw discussed the future of health care at this year's Google Zeitgeist conference in Paradise Valley, Ariz. Zeitgeist Minds brings together the top global thinkers and leaders across a wide spectrum including social, economic, political and cultural disciplines.
Tom Brokaw began the discussion "Facilitating Cooperative Efforts Towards Affordable Health Care for All", by stating how "nothing has an impact on society, and the welfare of society, more than health care". He then asked Dr. Noseworthy several questions related to the:
Watch the entire interview below to hear Dr. Noseworthy's responses and more!
September 11th, 2014 · Leave a Comment
Optum Labs, the collaborative research and innovation center co-founded by Optum and Mayo Clinic, announced the addition of four new partners committed to improving the quality and value of patient care. These new partner organizations, which represent a cross-section of health care stakeholders, are:
Optum Labs, with the largest, de-identified patient database in health care, is the first open, collaborative research and innovation center designed to accelerate health care innovation, leading to improved patient care and patient value. Read more…
September 8th, 2014 · Leave a Comment
This post originally appeared in the Mayo Clinic Center for Innovation blog. The Mayo Clinic Transform symposium is a multidisciplinary conference for thought-provoking, inspiring ideas hosted by the Mayo Clinic Center for Innovation and takes place Sept. 7–9. View the entire schedule of renowned speakers on the Transform website. If you can’t be there in person, you can watch the Transform live webcast via an external link. You're encouraged to participate digitally and virtually, in the many TweetChats. Feel free to share with your peers outside of Mayo Clinic. See webcast schedule for these digital times that have been built into the webcast — when normally the stage is “dark” during several networking times. This year, Transform has attendees from more than 14 countries and 30 states. For the first time ever, Mayo Clinic patients can watch and participate in Transform by tuning into patient channel 10. Watch this video of TXFM 2013 to hear participants try to sum up Transform in one word. Once again, journalist and commentator John Hockenberry will moderate the symposium discussions that include the following speakers:
To keep in touch with the growing transform community, join TransForum, the Center for Innovation’s online community with over 1,000 members working to transform the experience and delivery of health and health care. This online social media platform allows people to connect, create discussion groups throughout the year. The Center for Innovation is planning to bring presentations and discussion to TransForum throughout the year to keep the conversations going.
August 21st, 2014 · Leave a Comment
The future of health care needs to provide answers to the people who need them most -- the patients living with diseases and conditions that threaten their health and their lives. How is Mayo Clinic addressing this need in today's challenging health care environment? One solution lies in the efforts of Mayo Clinic Ventures and Mayo physicians and scientists who are working towards mining inventions, ideas and discoveries that will truly transform health care by improving the health and well-being of patients throughout the world.
Here's a recent post published on Mayo's In the Loop blog, which uniquely captures how Mayo Clinic Ventures makes it all happen:
"When you think about entrepreneurs and breakthrough inventions, you might imagine someone tinkering with a gadget (perhaps a doohickey or thingamajig) in a garage. You might not, however, picture a Mayo researcher tinkering with peptides to fight hypertension, creating a tracking system for viruses, or fashioning a tool to make medical information easier to read for those with poor vision. But our friends at Mayo Clinic Ventures would like us to, and a recent article series in the Minneapolis/St. Paul Business Journal gets under the hood to explore why.
Mayo's efforts to encourage entrepreneurship and support startups is not only good for medicine, but as writer Katharine Grayson suggests, bringing new ideas to the marketplace also has the potential to 'broadly impact Minnesota’s economy, with more Mayo business offspring growing up in (our own) backyard.' Jim Rogers, chair of Mayo Clinic Ventures, which commercializes Mayo Clinic technologies, tells Grayson that has meant a bit of a culture shift. And it’s required the assistance of efforts like the Mayo Clinic Business Accelerator, which provides collaborative space for new companies, venture capital firms and entrepreneurs.
To illustrate the potential of entrepreneurial endeavors, Grayson profiles three startups in a series called 'Made at Mayo.' The first article, “Mayo professor doubles as founder of text tech company,” chronicles the work of Randall Walker, M.D., Infectious Diseases, who started a company to create 'software that converts text into an easier-to-read format.' He was 'inspired by his own family history … to help people with low vision read easier,' Grayson writes. Walker Reading Technologies recently moved into the Business Accelerator space and is now working with Mayo 'to research how his text-conversion technology, called Live Ink, could make electronic medical records easier to read and manage.'
— Mayo Clinic Ventures (@MayoInvents) August 5, 2014
In another piece, called “Oncology professor launches startup to track cells and viruses,” the Biz Journal explores the work of Mayo’s Kah Whye Peng, Ph.D., to turn 'her scientific research into the foundation for a growing startup company.' Imanis Life Sciences 'sells tools and services that create a GPS-like tracking system for cells and viruses.' That allows researchers to 'use imaging technology to monitor therapies’ progress inside living animals.' And a piece called “Zumbro uses custom peptides to battle hypertension” documents the work of John Burnett, M.D., and Horng Chen, M.D. 'Their latest venture, Zumbro Discovery Inc.,' Grayson writes, 'uses peptides to treat high blood pressure in patients who haven’t benefited from traditional drugs.' Dr. Burnett says the company expects to begin clinical trials yet this year, expects to grow significantly, and its 'goal is to be the next Amgen.'
Read more about the big plans for these ventures, as well as the business behind the business, in the Business Journal series."
August 13th, 2014 · Leave a Comment
This post originally appeared in the Mayo Medical Laboratories blog.
Franklin Cockerill, M.D., chair of the Mayo Clinic Department of Laboratory Medicine and Pathology, participated in the 21st Century Cures Roundtable on Personalized Medicine hosted by the U.S. House of Representatives Energy and Commerce Committee on Wednesday, July 23.
Throughout Dr. Cockerill’s remarks, he emphasized the importance of providing proper government funding for research and regulatory bodies, harmonizing regulations, emphasizing clinical validation, ensuring patient safety, and encouraging innovation. A summary of Dr. Cockerill’s remarks have been embedded below.
According to the committee’s website, the 21st Century Cures Roundtable next brings together industry leaders to, “discuss how the rise of personalized medicine and advances in science and technology can shape the health care system in the 21st century. Specifically, the roundtable will explore how genomic sequencing and diagnostic testing, as well as the regulation of these continually evolving areas, affect innovative product development and delivery.”
Key Points from Dr. Cockerill's Remarks:
Focus on harmonizing regulations, emphasizing clinical validation, ensuring patient safety & encouraging innovation. - Cockerill #path2cures
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014
Challenges: Govt funding of scientific discovery & translating discoveries to clinical tests that benefit patients.- Cockerill #Path2Cures
— Mayo Medical Labs (@mayocliniclabs) July 23, 2014
July 30th, 2014 · Leave a Comment
Mayo Clinic wants to help 200 million patients by 2020. That's the future of health care vision of John Noseworthy, M.D., president and CEO of Mayo Clinic. He recently shared his plans with The Daily Briefing on how to accomplish this goal by:
1) Scaling Mayo Clinic's knowledge with the continued growth of the Mayo Clinic Care Network to provide seamless, high-quality, team-based care.
2) Applying innovative science and data to evaluate the quality, safety and value of health care globally and improve real-world experiences for patients through the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery.
3) Partnering with Optum to launch Optum Labs, an open, collaborative research and development facility, to collect and analyze patient data that will determine how health care providers can provide the safest care with the best patient outcomes.
Read the entire interview here to learn more about these plans as well as Dr. Noseworthy's recommendations for those who aspire to become health care leaders.
July 23rd, 2014 · Leave a Comment
Wait no more for the transition to genomic medicine as we look towards the future of health care. It’s here, and it’s changing the way doctors care for everything from cancer to diabetes and Alzheimer’s disease. But the reality is that most physicians report insufficient knowledge to maximize the benefits of these powerful new tools on behalf of their patients.
Mayo Clinic is changing that with the Individualizing Medicine Conference series, the world’s largest meeting geared towards helping providers of all stripes discover and discuss the latest tools in individualized medicine. The goal is to cultivate new skills in providers, pharmacists and researchers so that they take those techniques back to their practices and help improve care for patients around the world. [...]
July 16th, 2014 · Leave a Comment
The future of health care in the United States requires modernization of clinical trial regulations and processes. On July 9, I had the opportunity to deliver that message and stress its importance in testimony on behalf of Mayo Clinic before the U.S. House of Representatives Energy and Commerce Subcommittee on Health. As part of the full Committee’s 21st Century Cures Initiative, the Health Subcommittee held a hearing focused on policy issues surrounding clinical trials. I applaud the Committee’s interest in this issue and urge continued focus on the need for reform to reduce the length of time from target discovery to approval of new drugs and treatments.
As I reported to the Committee, the average length of time from target discovery to approval of a new drug currently averages approximately 14 years, the failure rate exceeds 95 percent, and the cost per successful drug exceeds $2 billion, after adjusting for all of the failures. This situation must change.